Dr. Vaishampayan on the Future Directions for Second-Line Treatment in Urothelial Cancer

Partner | Cancer Centers | <b>University of Michigan Rogel Cancer Center</b>

Ulka Nitin Vaishampayan, MBBS, discusses future directions for second-line treatment in urothelial cancer.

Ulka Nitin Vaishampayan, MBBS, director, Phase I Program, Rogel Cancer Center, Michigan Medicine,professor of internal medicine, University of Michigan, discusses future directions for second-line treatment in urothelial cancer.

Beyond chemotherapy, several novel treatment options are available for the management of urothelial carcinoma, and it is important to profile tumors to inform available options, Vaishampayan explains. Moreover, as chemotherapy and immunotherapy are moving into earlier-line settings, some of the second-and third-line options will likely be moved earlier in the disease state, including the frontline setting, for patients with metastatic disease, Vaishampayan adds.

Antibody-drug conjugates (ADCs) have demonstrated remarkable efficacy in patients with advanced urothelial cancer, Vaishampayan continues. Currently, 2 ADCs are FDA approved, both utilizing distinct mechanisms of actions and associated with different safety profiles of non-overlapping toxicities, Vaishampayan concludes.